Compare YSS & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSS | EWTX |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | 710 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 3.7B |
| IPO Year | N/A | 2021 |
| Metric | YSS | EWTX |
|---|---|---|
| Price | $16.91 | $40.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $36.56 | ★ $39.00 |
| AVG Volume (30 Days) | 1.1M | ★ 1.1M |
| Earning Date | 03-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $48.43 | N/A |
| Revenue Next Year | $52.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.93 | $12.31 |
| 52 Week High | $44.54 | $48.40 |
| Indicator | YSS | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.61 | 52.30 |
| Support Level | N/A | $37.81 |
| Resistance Level | $35.56 | $43.93 |
| Average True Range (ATR) | 1.74 | 2.69 |
| MACD | -0.13 | -0.52 |
| Stochastic Oscillator | 1.91 | 29.06 |
York Space Systems Inc is a U.S.-based space and defense company that provides mission-related solutions for national security, government, and commercial customers. The company develops its own hardware and software, offering capabilities intended to support customer requirements across various elements of the space mission lifecycle. It offers mission solutions across several complementary product categories: Components, Subsystems, Spacecraft Platforms, Ground Operation, Global Downlink, and Software-Enabled Services. The company derives the majority of revenue from long-term firm-fixed-price (FFP) production contracts for the design of small satellites, launch services, and ground services with both U.S. federal government-controlled agencies and domestic commercial customers.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.